The Action of Thiethylperazihe Torecan®), a New Anti-Emetic, Compared

Total Page:16

File Type:pdf, Size:1020Kb

The Action of Thiethylperazihe Torecan®), a New Anti-Emetic, Compared TH,'E ACTION OFf THIETHYLPERAZI!~Ei: ~ITO!~ECANr A NE'~( ANTI''-- EMETIC, COMPARED,' WITH:". PER[P:NHE' i ' q[AZINE ' ( TRILAFON|:'1 L TR~METHOBENZAMIDE (TIGAN| AND[A PI.ACE~O IN THE" suPPRESSION OF POSTANAESTHETI~NAIUSEN AND V()MITING IAN E. PtrnICIS, M.B., B.S., ~.F.A..I~.C.S.O POSTa_Na_ESTH~TIC VOMITING has been ~shown ~0 b(l" i~ffffeneed ]~y a varie]ty of factors, and it is therefore unlikely that any a~i-ergetie drug will be completely effective and without side-effects in all patients. In[the absence of any ele~r-eut superiority of one drug over another,-the physi4ian naust exercise a choicK selecting a drug with minimum side-effects but maximum anti-emetic effect. This choice can only be made on the basis of ieontrolled studies of effectir and side-effects, since clinical impressions can be nlost misleading.~ Malay ~igents can be shown to have an anti-emetic effect wl~n e0mpared I with a placebo (e.g., atropine) 1 but they may not be clinically us,~fuI as anfi-erneties. If new drug can be shown to have an effect equal to ~or better than a drug whi, .a has proven highly effective against a strong clinica,l challenge, then it is likeb that the new agent will be clinically useful. Thiethylperazine (Toreean| is a phenothiazin Which possesses to a very marked degree the anti-emetic activity common to all drugs, of this group, while the other group activities of lowering bk od pressure,~=.potentiatign of narcotics and barbil~urates, and extrapyramidal et feets, are minimized. 2 There have been a numberl of reports of its anti-emetic ef ?ect compared with a plgcebo in man, ~.4,~ and there is experimental evidence :o suggest that its medullary action is not confined to the Chemoreceptor Trig ger Zone (CTZ) but elacom- passes the vomiting centre as welI2 Perphenazine (Trilafon| was c~sen as a comparative standard, since this drug had ranked as the most effective agent of four in ra/~revious comparative triald ~4z the same time the opportunity was taken l to corhpare these two ~,tgents with tnmethobenzamlde:;. (Tlgan (~ ) m........ high, dosage, since chmcally this latterI drug appeared to have minimal anti-emetic'~activlty.8 METHOD A previous triaF had shown that the highest incidence of emetic symlptoms followed the operations of abdominal hystereqtomy, vaginal hystereqtomy, and cholecystectomy, and that symptoms werejmore than twice as common in female patients as in ~ale. Accordingly, female patients undergoing hysterectomy and cholycystectomy were selected for this survey in order to provide ~ high *Department of Anaesthesia, Victoria General Hospital and Dalhousie University, Halifax, Nova Scotia. This study was supported by a grant-in-aid from Sandoz Pharmae~uticals (Canada) Ltd., whose assistance in statistical analysis and preparation of figures is gratefully acknowledged. 595 Can. Anaes. Soc. J., vol. 12, no. 6, November, 1965 I CANADIAN ANA]~STHETIS~" S~ ]OUBNAL! clialienge for the test drugs. All patients rec~@ed a standardpremedication of meperidine (Demerol) and atropm~,~:a~d a standard anaesthetic sequence of thiopentone' J ~' " induction with maint~nanl;~" "b '"~!n nitrous-oxide-ox)~gen-halotha~o~," " ' :~ I succinylcholiiie being used for relaxatio, as '.required. The,. test druust_J were coded m batchesI /in ~dentieal'i wals, and' :he aor)roonatej.s, J. ! dose of the selected drug was given by ntramuscular injecti6n :o each patient mcluded" m the" trial as she arrived i~a ti b recovery: room. The sr] lection ~ of drugI was dictated by reference to a randc)m llocatmn sheet for each operation, and the amount of drug was made prop(~rti( ml to body weight, by ~iving 0.04 ic.c. of test solution per pound of body We ,ht Peruhenazine was diluted to i.25 mg./e.c., ttimethobenzamide to 100 mg./'c:.c, and thiethylperazin~ to 5 mg./c.c. usin~ sterile 5 uer cent dextrose water, /which was also used f,)r the placebo. The'~l~10-pound ~patient, for example~ thus received~-7 mg. of perphenazine, !560 mg. of trimethobenzamide, or 28 mg. of thiethyl, perazine. All patients were Observed for two ho~rs m the recovery room, and incidents of nausea and vomiting were charted at 15-minute intervals using[ a score system. A complaint of nausea was scored as onc observed retchin~ ' or~gagging without lkluid emesis was scored as two, while each e uisodFe of liauid emesis scored three. Patients were visited betwee n 24 and 48 hours after operation, and t e me, dents cOl nausea and vomatmg recorde on the patient s chart were ~correlated wi~ thd/patiefit's observations, and" scored in the same way. Scores rlaade in ,. /. r the fir~t~15~,7~-: minutes were disreKarded,~ since it was felt thatY., the|test_ aKent had not b~6gun to act during this period. RESULTS On conclusion of the survey, the obs,~rvations, together with the identityof the test agents, were translated into a numerical code and placed on punch cards The data was subjected to a 3 X 3 X 4 factorial design analysi: which demon- stratbd that there was no significant difference in scores among he three chosen operative sites, that all sites had equal Lqfluence~on the emetic scores at different TAB.EL I , 3 X 3 X 4 FACTORIAL DESIGN ANALYSIS SHOWING SIGNIFICANT DIFFERENCES I3ETWEEN .TEST DRUGS AND TIME PERIODS, BUT N~D~ SIGNIFICANT. EFFECT. OF OPERATIVE..... SITE. ,ON'~.... DRU'GS./oR ~TIME2_. _ , , , , Source df Sum of squares Mean square F" ,, p Between Patients 331 2,980,. 6.55 Between drugs 3 I 118,.869 39.623 4.466 -<0.005 Between operations 2; 4:.798 2.399 2~0 n.s. Drug X operation interaction 6 17.816 2.969 335 n.s. Residual 320 2,839.172 8.872 Within Patients 664 2,793~333 Between periods 2 269. 774 134. 887 36.056 <0.00(1( Drug X period interaction 6 58. 661 9. 777 2. 613 <0.02,5 ~ Operation X period interactioia 4 18. 520 4. 630 1 238 n.s. Drug X Operation X period interacti0h ~ i2 511904 4.325 1. 156' 13, S. Residual fi40 2,394.474 3.741 Total 995 5,773. 988 J,, r , i , ' I. PUmKIS: THE ACTION OF TRIEq~-IYLI I~RAZINE 597 time periods, and that there was no interaction bet:ween the test drugs and the operative site (Table L). The data from all operations could thus be colnbi~ed, and was analysed with reference to incidence and ~severity of emetic sympt(~ms , and to the side effects of hypotension in the recovery room, potentiation of Inareotics~ and prolongation of postoperative sleep. Incidence of Emetic Symptoms Table II shows the increase in emetic syrnpfoms / in each group of patients with the passage of time. Thiethylperazine was given Io 86 patients, of whom 33.7 per cent showed sypm toms in the first two h~urs.~No more patients vomited during the next four hours, but by twenty-four hour~, 54..7 per cent had shown symptoms. Of the 79 patients receiving perphenaz [ne, 24.1 per cent showed symptoms after two hours, and 27.8 per cent after sk: hours, butday wenty-four hours, 48.1 per cent had shown emetic symFgoma These figures compared favourably with the placebo group of 83 patients, where 44.6 per cent were affected in the first two hours, the figure rising to 5( ~.6 per cent after six hoUrs, and reaching 66.3 per cent over the twenty-four ho ar p,e/iod. In contrast, 40.5 per cent of the 84 patients receiving trimethobenza: hide had symptoms in the first two hours, and the percentage increased to 52 .4 per cent after six hours and 82.1 per cent after twenty-four hours. The perc entage of patients showing symptoms in t~ese last two periods was thus grea',Lter than that seen in the placebo group. Statistical analysis of these figures (Table III) shows perphenazine to be significantly more effective (p < 0.05) than the other agents at two hours, but over the six-l~our period, perphenazine loses some of its effectiveness, wihile thiethylperazine does not, and thiethylperazine emerges as significantly more effect'iw~ than/placebo or trimethobenzamide over the six-hour period. Trimetho- benzamidemo~ w ranks as less effective than the plac,ebo~a"t this period, and ,this difference becomes significant over the twenty-four-hour period. Both perphenazine and triethylperazine are significantly superior to both placebo and trimetho- benzamide over the twenty-four-hour period, with perphenazine ranking as the most effective. The differences between perphenazine and triethylperazine are not significant on the basis of these incidence comparisons. The f es ul ts are shown graphically in FigUre J:. Severity of Emetic Symptoms: The average score for emetic symptoms (includ:l[ng ,;cores of Zero.) for all patients is shown in Table IV. VVith thiethylperazine, the average was' 1..035 over the first two hours, rising, to 1.326 over the six,hour period, and reaeMng 2~ for the full twenty-four',hour period. Perphenaizine was slightly less efFec- tive, the scores for the three(iperiods being 1.127, 1.747, and 3.266. Trimetho- benzamide was less effective than the other drugs, !with average scores of 1.381, 2.083, and 4.560 over the three time periods, but !t was still more effective than placebo, which showed average scores of 2.325, ~,]120, and 5,241 at these thnes. N-" Ir.-'-~ - . .,u---~---4 O qt T . G m ~ ~--o 4 rT') "5 A m O O O q 0 I.
Recommended publications
  • Postoperative Vomiting: a Review and Present Status of Treatment
    POSTOPERATIVE VOMITING: A REVIEW ~ND ~?RESENT STATUS OF TREATMENT* L. E. SI2vlONSEN, M.D., C.NI., and S. L. VANDEWAjTER,M.D., r.R.c.r. (c.) t POSTOPERATIVE VO~vlITING remains one of the most I frequent complications en- countered by the anaesthetist. Although considered no|more than a nuisance complication, it can, in certain cases, contribute to more ~lSan just discomfort for the patient; it can threaten his very life either immediately through aspiration, or later by serious loss bf fluids and electrolytes. It cap also add considerable strain on some operation wounds. After Wang and Boxison 1 further delineated the vomit ng centre in 1952, most of the succeeding research and investigation into the ~ontrol of vomiting has centred about those drugs that have a depressant actio 1 on the chemoreceptor trigger zone (C.T.Z.). Out of these investigations have c ~me much valuable and interesting data which the anaesthetist may use as additio ns to his ever-expanding resources to provide safety and comfort to the surgical patient. THE VOMXTn~OCENTaE Neurophysiologists have long accepted the existence of a vomiting centre. Located in the medulla in the solitary tract and the dgrsal part of the lateral reticular formation, it lies in close relationship to ma:ay other centres whose functions are associated with the vomiting act such ts salivation, spasmodic respiratory movements, and forced inspiration. ~ Lying lorsolateral to the vagal nuclei and close to the vomiting centre in the area pos :rema of thefloor of the fourth ventricle is an accessory vomiting centre which Ihas been designated as the C.T.Z.
    [Show full text]
  • Parkinson's Disease Fact Sheet
    Parkinson’s Disease Fact Sheet About Parkinson’s Disease Parkinson’s disease is a progressive, incurable neurological disorder associated with a loss of dopamine-generating cells in the brain. It is primarily associated with progressive loss of motor control, but it results in a complex array of symptoms, including many non-motor symptoms. Parkinson’s impacts an estimated one million people in the United States. Critical Clinical Care Considerations • To avoid serious side effects, Parkinson’s patients need their medications on time, every time — do not skip or postpone doses. • Write down the exact times of day medications are to be administered so that doses are given on the same schedule the patient follows at home. • Do not substitute Parkinson’s medications or stop levodopa therapy abruptly. • Resume medications immediately following procedures, unless vomiting or severely incapacitated. • If an antipsychotic is necessary, use pimavanserin (Nuplazid), quetiapine (Seroquel) or clozapine (Clozaril). • Be alert for symptoms of dysphagia (trouble swallowing) and risk of pneumonia. • Ambulate as soon as medically safe. Patients may require assistance. Common Symptoms of Parkinson’s Disease Motor Non-Motor • Shaking or tremor at rest • Depression • Bradykinesia or freezing (being stuck • Anxiety in place when attempting to walk) • Constipation • Low voice volume or muffled speech • Cognitive decline and dementia • Lack of facial expression • Impulse control disorders • Stiffness or rigidity of the arms, legs • Orthostatic hypotension or
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Together with CCHP's Medication List Prior Authorization Is Required If Indicated by X(PA)
    Together with CCHP's Medication List Prior authorization is required if indicated by X(PA). Pharmacy Benefit: Submit authorizations through Together with CCHP's Pharmacy Services. Medical Benefit: Submit authorizations through CareWeb Qi Authorization tool. Jcode Brand Name Description Pharmacy Medical Notes J3365 Abbokinase INJECTION, UROKINASE, 250,000 IU X J0287 Abelcet INJECTION, AMPHOTERICIN B LIPID X COMPLEX, 10 MG J0401 Abilify Maintena INJECTION, ARIPIPRAZOLE, EXTENDED X X May bIll eIther RELEASE, 1 MG (PA < 12 YEARS OF benefIt, PA AGE) reQuIred when bIllIng through pharmacy INJECTION, PACLITAXEL PROTEIN- J9264 Abraxane BOUND PARTICLES, 1 MG X J7613 Accuneb ALBUTEROL, INHALATION SOLUTION, X FDA- APPROVED FINAL PRODUCT, NONCOMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE, 1 MG J0132 Acetadote INJECTION, ACETYLCYSTEINE, 100 MG X J7608 Acetylcysteine ACETYLCYSTEINE, INHALATION X SOLUTION, FDA- APPROVED FINAL PRODUCT, NONCOMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER G J3262 Actemra INJECTION, TOCILIZUMAB, 1 MG X (PA) J0800 Acthar Gel INJECTION, CORTICOTROPIN, UP TO 40 X (PA) UNITS J0795 Acthrel INJECTION, CORTICORELIN OVINE X TRIFLUTATE, 1 MCG J9216 Actimmune INTERFERON GAMMAM 1-B X (PA) J2997 Activase INJECTION, ALTEPLASE RECOMBINANT, X 1 MG J2504 Adagen PEGADEMASE BOVINE 25 IU X (PA) J2062 Adasuve LoxapIne, InhalatIon powder, 10 mg X INJECTION, BRENTUXIMAB VEDOTIN, 1 J9042 Adcetris X MG 1 Together with CCHP's Medication List Prior authorization is required if indicated by X(PA). Pharmacy Benefit: Submit authorizations
    [Show full text]
  • Neuroleptic Malignant Syndrome in the Acquired Immunodeficiency Syndrome
    Postgrad Med J 1997; 73: 779-784 (© The Fellowship of Postgraduate Medicine, 1997 HIV medicine Postgrad Med J: first published as 10.1136/pgmj.73.866.779 on 1 December 1997. Downloaded from Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome Jose L Hemaindez, Luis Palacios-Araus, Santiago Echevarria, Andres Herran, Juan F Campo, Jose A Riancho Summary The neuroleptic malignant syndrome (NMS) is a life-threatening process, Patients infected by the human typically, but not exclusively, induced by drugs of the neuroleptic group. Its immunodeficiency virus are pre- main clinical manifestations include fever, rigidity of skeletal muscles, disposed to many infectious and fluctuating consciousness and autonomic disturbances.' Since first described noninfectious complications and by Delay and Deniker in 1968,2 the syndrome has received increasing attention often receive a variety of drugs. and more than 1600 cases have been reported to date, including a few cases in Furthermore, they seem to have a patients with the acquired immunodeficiency syndrome (AIDS).3-8 Never- particular susceptibility to idio- theless, outside psychiatry, the syndrome probably remains underdiagnosed, as syncratic adverse drug reactions. its manifestations may be also caused by other processes such as infections and It is therefore surprising that only neoplasms. Thus, a high index of suspicion is needed to not miss the diagnosis a few cases of the neuroleptic in medical patients. This is particularly important in patients infected by the malignant syndrome have been human immunodeficiency virus (HIV), who commonly suffer infectious described in patients with the complications but also often receive psychoactive drugs. This article reviews acquired immunodeficiency syn- the main features of NMS in AIDS patients.
    [Show full text]
  • High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury
    DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 DMD FastThis Forward.article has not Published been copyedited on and January formatted. 24, The 2014final version as doi:10.1124/dmd.113.056267 may differ from this version. DMD #56267 High daily dose and being a substrate of Cytochrome P450 enzymes are two important predictors of drug-induced liver injury Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina Ilic and Weida Tong Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Downloaded from US Food and Drug Administration, Jefferson, AR, USA (K.Y., M.C., J.Z., W.T) National Center for Safety Evaluation of Drugs, National Institute for Food and Drug Control, China's State Food and Drug Administration, Beijing, China (X.G.) dmd.aspetjournals.org Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, China (B.W.) Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia (K.I.) at ASPET Journals on September 24, 2021 1 Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56267 Running title: Two important predictors for drug-induced liver injury Corresponding authors: Katarina Ilic, Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, 450 Vojvode Stepe, Belgrade 11221, Serbia. E-mail address: [email protected]. Weida Tong, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, Downloaded from AR 72079, USA.
    [Show full text]
  • One Step Multi-Drug Screen Test Cup Package Insert
    Fentanyl (FEN) Fentanyl 300 the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if One Step Multi-Drug Screen Test Cup Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher Fentanyl (FEN) Fentanyl 200 than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, Package Insert Fentanyl (FEN) Fentanyl 100 gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception. Only trace amounts (less than 1%) of most Benzodiazepines are excreted Cotinine (COT) Cotinine 200 Package insert for testing of any combination of the following drugs: Methamphetamine, unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period Amphetamine, Cocaine, Morphine, Ecstasy, EDDP (Methadone Metabolites), Tricyclic 6-Monoacetylmorphine (6-MAM) 6-Monoacetylmorphine 10 for the Benzodiazepines in the urine is 3-7 days. Antidepressants, Oxycodone, Barbiturates, Buprenorphine, Phencyclidine, K2 (Synthetic Methaqualone (MQL) Methaqualone 300 Cannabinoid), Ketamine, Methaqualone, Methadone, Fentanyl, Tramadol, Ethyl Glucuronide, OXYCODONE (OXY) Cotinine, 6-Monoacetylmorphine, Methylenedioxypyrovalerone, Lysergic acid diethylamide, Ketamine (KET) Ketamine 1,000 Oxycodone, [4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-one, Marijuana and Benzodiazepines. Ketamine (KET) Ketamine 100 dihydrohydroxycodeinone] is a semi-synthetic opioid agonist derived from thebaine,
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff Et Al
    US006528521B2 (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff et al. (45) Date of Patent: Mar. 4, 2003 (54) TREATMENT OF ANTI-DEPRESSION DRUG- 5,756.483. A 5/1998 Merkus ....................... 514/58 INDUCED SEXUAL DYSFUNCTION WITH 5,770,606 A 6/1998 El-Rashidy et al. ........ 514/284 APOMORPHINE 5,866,164 A 2/1999 Kuczynski et al. ......... 424/472 5,897.864. A 4/1999 Cohen ..................... 424/195.1 5,939,094. A 8/1999 Durif et al. ................. 424/448 (75) Inventors: 3. P slot, NSS). 5,945,117 A 8/1999 El-Rashidy et al. ........ 424/430 (73) Assignee: Tap Pharmaceutical Products, Inc., OTHER PUBLICATIONS Lake Forest, IL (US) Marketletter of Jul. 17, 1995 (abstract).* (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Wilson, E.K., Chemical & Engineering News, 76(26), pp. 29 U.S.C. 154(b) by 0 days. (Jun. 29, 1998). (21) Appl. No.: 09/993,782 * cited by examiner (22) Filed: Nov. 14, 2001 O O Primary Examiner Phyllis G. Spivack (65) Prior Publication Data (74) Attorney, Agent, or Firm- Wood, Phillips, Katz, Clark US 2002/0115683 A1 Aug. 22, 2002 & Mortimer Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 60/249,031, filed on Nov. 15, A method for treating Sexual dysfunction that is caused by 2000. anti-depressant medication in a patient in need of Such (51) Int. Cl. .............................................. A61K 31/473 treatment, comprising administering a therapeutically effec (52) U.S. Cl. ....................................................... 5141284 tive amount of apomorphine, or a pharmaceutically accept (58) Field of Search .........................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
    [Show full text]
  • Procedure Codes, Section 3
    NEW YORK STATE MEDICAID PROGRAM PHYSICIAN – PROCEDURE CODES SECTION 3 - DRUGS and DRUG ADMINISTRATION Physician – Procedure Codes , Section 3- Drugs and Drug Administration _____________________________________________________________________________ Table of Contents GENERAL RULES AND INFORMATION ............................................................2 MMIS DRUG MODIFIERS ....................................................................................4 DRUGS.................................................................................................................5 IMMUNE GLOBULINS...................................................................................................5 VACCINES, TOXOIDS ..................................................................................................5 HYDRATION, THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS (EXCLUDES CHEMOTHERAPY) .....................................................8 DRUGS ADMINISTERED OTHER THAN ORAL METHOD.........................................10 CHEMOTHERAPY ADMINISTRATION.......................................................................19 CHEMOTHERAPY DRUGS.........................................................................................21 Version 2008 – 1 (5/15/2008) Page 1 of 23 Physician – Procedure Codes , Section 3- Drugs and Drug Administration _____________________________________________________________________________ GENERAL RULES AND INFORMATION 1. BY REPORT: A service that is rarely provided, unusual, variable,
    [Show full text]
  • High-Risk Medications in the Elderly
    High-Risk Medications in the Elderly The Centers for Medicare & Medicaid Services (CMS) contracted with the National Committee for Quality Assurance (NCQA) to develop clinical strategies to monitor and evaluate the quality of care provided to Medicare beneficiaries. The NCQA’s Geriatric Measurement Advisory Panel identified several categories of medications that have an increased risk of adverse effects to elderly patients. The enclosed chart identifies several key medication categories that CMS and NCQA are monitoring. In an effort to ensure patients’ safety, many of our clients have established pre-authorization protocols for those prescriptions for high risk medications in patients older than 65 years of age. Since pharmacists have a very important role in patient care, we want you to be part of this safety initiative. We strongly encourage that you contact the prescriber when your elderly patient is requesting a new or refilled prescription of a high-risk medication listed on the below chart. Category High Risk Medications Alternatives Analgesics butalbital/APAP Mild Pain: butalbital/APAP/caffeine (ESGIC, FIORICET) acetaminophen, codeine, short-term NSAIDs butalbital /APAP/caffeine/codeine Moderate/Severe Pain: butalbital/ASA/caffeine (FIORINAL) tramadol (ULTRAM), tramadol/APAP* (ULTRACET), butalbital/ASA/caffeine/codeine morphine sulfate (MS CONTIN), ketorolac (TORADOL) hydrocodone/APAP (VICODIN, etc.), oxycodone indomethacin (INDOCIN) (OXYIR), oxycodone/APAP (PERCOCET), fentanyl meperidina (DEMEROL) patch (DURAGESIC), OXYCONTIN
    [Show full text]
  • CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No
    US010064856B2CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No. : US 10 , 064 ,856 B2 Bosse et al. ( 45 ) Date of Patent: * Sep . 4 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITIONS (52 ) U .S . CI. ??? . .. A61K 31/ 485 ( 2013 .01 ) ; A61K 9 / 209 @(71 ) Applicant : LOCL PHARMA , INC . , Las Vegas , ( 2013 . 01 ) ; A61K 9 / 2013 ( 2013 . 01 ) ; A61K NV ( US ) 9 /2027 ( 2013 .01 ) ; A61K 9 / 2054 ( 2013 .01 ) ; A61K 9 / 4808 ( 2013 .01 ) ; A61K 31 / 165 @(72 ) Inventors : Paul Bosse, Jupiter , FL (US ) ; John ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Ameling , Jupiter, FL (US ) ; Bernard 31/ 24 ( 2013 .01 ) ; A6IK 31/ 403 ( 2013 .01 ) ; Schachtel, Jupiter, FL (US ) ; Ray A61K 31/ 404 (2013 .01 ) ; A61K 31 /4196 Takigiku , Loveland , OH (US ) ( 2013 . 01 ) ; A61K 31/ 422 ( 2013 . 01 ) ; A61K 31 / 437 ( 2013 .01 ) ; A61K 31/ 454 ( 2013 .01 ) ; @( 73 ) Assignee : LOCAL PHARMA , INC ., Las Vegas , A61K 31 /515 ( 2013 . 01 ) ; A61K 31/ 522 ( 2013 . 01 ) ; A61K 31 /5415 ( 2013 .01 ) ; A61K NV (US ) 45 / 06 ( 2013 .01 ) ; A61K 9 / 0024 ( 2013 .01 ) ; @( * ) Notice : Subject to any disclaimer , the term of this A61K 9 / 0056 ( 2013 . 01 ) ; A61K 9 / 1694 patent is extended or adjusted under 35 ( 2013 . 01 ) ; A61K 9 /2086 ( 2013 . 01 ) ; A61K U . S . C . 154 (b ) by 0 days . 47 / 36 ( 2013 .01 ) (58 ) Field of Classification Search This patent is subject to a terminal dis None claimer . See application file for complete search history . ( 21 ) Appl. No .: 15 / 683, 635 ( 56 ) References Cited ( 22 ) Filed : Aug . 22, 2017 U . S . PATENT DOCUMENTS 3 ,048 , 526 A 8 / 1962 Boswell (65 ) Prior Publication Data 3 , 108 , 046 A 10 / 1963 Harbit 3 , 536 ,809 A 10 / 1970 Norman US 2017 /0348303 A1 Dec .
    [Show full text]